Research programme: macrocyclic peptide therapeutics - PeptiDream/Shionogi
Latest Information Update: 18 Feb 2016
At a glance
- Originator PeptiDream; Shionogi
- Class Macrocyclic compounds; Peptides
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 05 Feb 2016 Early research in Undefined indication in Japan (unspecified route)
- 05 Feb 2016 Shionogi and PeptiDream agree to co-develop and co-promote macrocyclic/ constrained peptides in Japan